Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reduced their target price on shares of Oncternal Therapeutics from $28.00 to $19.00 and set a buy rating on the stock in a report on Monday, May 13th.

Oncternal Therapeutics Stock Performance

NASDAQ:ONCT opened at $9.00 on Friday. The stock has a market capitalization of $26.64 million, a P/E ratio of -0.73 and a beta of 1.28. The company has a 50 day moving average price of $8.60 and a 200 day moving average price of $8.53. Oncternal Therapeutics has a fifty-two week low of $5.57 and a fifty-two week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.88) by $0.05. The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.18 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same quarter last year, the company posted ($4.00) EPS. Research analysts forecast that Oncternal Therapeutics will post -10.12 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Robert James Wills purchased 3,086 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $8.96 per share, for a total transaction of $27,650.56. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $89,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have bought 10,714 shares of company stock worth $92,736. 11.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Oncternal Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantum Private Wealth LLC acquired a new stake in Oncternal Therapeutics during the 1st quarter worth $250,000. Richmond Brothers Inc. grew its position in Oncternal Therapeutics by 69.8% during the 3rd quarter. Richmond Brothers Inc. now owns 494,042 shares of the company’s stock worth $148,000 after purchasing an additional 203,010 shares during the last quarter. Finally, Pasadena Private Wealth LLC grew its position in Oncternal Therapeutics by 79.4% during the 4th quarter. Pasadena Private Wealth LLC now owns 500,000 shares of the company’s stock worth $268,000 after purchasing an additional 221,250 shares during the last quarter. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.